• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

special purpose acquisition company

SPAC special purpose acquisition company
Biotech

German cancer antibody biotech eyes SPAC as route to Nasdaq

Market turmoil may have frozen the traditional IPO pipeline, but Veraxa is turning to the SPAC model to hop onto the Nasdaq.
James Waldron Apr 23, 2025 6:09am
SPAC special purpose acquisition company

BridgeBio's cancer spinout backs SPAC as path to Nasdaq

Feb 28, 2025 9:25am
SPAC special purpose acquisition company

Medera plans SPAC merger to advance cardiac gene therapies

Sep 5, 2024 10:50am
metronome tempo pace

Adagio Medical picks up the tempo with $128M SPAC deal

Feb 15, 2024 1:40pm
Nasdaq

Abpro inks SPAC deal to fund bispecific R&D years after axed IPO

Sep 22, 2023 9:20am
SPAC special purpose acquisition company

Calidi goes public via SPAC to push allogeneic cancer therapies

Sep 13, 2023 9:35am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings